Gates, Google Join $120 Million Funding for Genome Editing Firm

Editas Medicine Inc. has raised $120 million from investors to support development of a technology that can precisely edit DNA and potentially treat fatal genetic diseases.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.